Description

Tesamorelin represents a sophisticated synthetic analogue of human growth hormone-releasing hormone, incorporating the complete 44-amino acid sequence of native GHRH with a specific N-terminal modification designed to enhance stability and biological activity. The compound features a trans-3-hexenoic acid group attached to the N-terminus, which significantly improves resistance to enzymatic degradation and extends the peptide’s half-life compared to unmodified GHRH. The peptide maintains the complete biological activity of native GHRH through specific binding to growth hormone-releasing hormone receptors in the anterior pituitary gland. Tesamorelin’s enhanced stability profile makes it suitable for various research protocols examining growth hormone physiology, pituitary function, and related endocrine mechanisms. The compound has been utilized in research investigating growth hormone regulation, metabolic effects of growth hormone-releasing hormone, and receptor pharmacology. For research use only.